MED TECH Europe have shared the attached HAI updated brochure. It is important to note that this is a revamp and update of an already existing information sheet, with new data, new calls for action (in line with our position paper) and a clear link made between AMR and HAIs. The brochure showcases the different medical technologies that can prevent and control HAIs throughout the patient pathway.
IMSTA SUBMISSION to Public consultation on draft guidance document relating to distribution of medical devices (including IVDs) completed.
Please follow links to view documents:
“This is a must see event for IMSTA members who want to compete for MES contracts in the future.”
THE FOLLOWING PRESENTATIONS ARE NOW AVAILABLE:
MES SEMINAR – Friday 21st April 2017
Registration – 10.00 to 10.30 a.m.
Venue – The Emmet Theatre, ARTS Building, TRINITY COLLEGE, Dublin 2.
No parking at venue, parking nearby in Setanta Centre.
Enter via Nassau Street Entrance.
For late registrations please contact Joanne on firstname.lastname@example.org
See Agenda here :MES Seminar Agenda
Justin Carty, CEO of IMSTA spoke with Irish Times journalist Sylvia Thompson
The cheapest product rarely gives customers the best value, according to Justin Carty, the CEO of the Irish Medical and Surgical Trade Association. Representing products ranging from bandages to CAT scans, Carty has to navigate a careful route when promoting the medical device industry to public and private hospital purchasers keen to get the best value for money with limited budgets.
But, as luck would have it, Carty’s agenda fits completely with the new EU public procurement directive. This 2014 EU directive presents a holistic analysis of value based health care which evaluates the entire life cycle, safety and effectiveness of products and not just the purchasing price. It also encourages the industry to define best price-quality ratio and to collaborate more closely with purchasers at the pre-tendering phase.
A recent report from the Boston Consulting Group, commissioned by Med Tech Europe (of which IMTSA is a member) presents a clear picture on how things need to change. Currently, most health care providers purchase medical products on the basis of the up-front purchase price, which, the consultants argue cloud the true cost of care.
The report includes insightful examples of what happens when broader criteria are used to purchase equipment. Take for instance, the Karolinska University Hospital in Sweden whose foutreen year tender for imaging services which included MRI, ultrasound and CT scanners; by tendering for imaging services rather than equipment, the contract included maintenance of technical standards, upgrades and replacement during the fourteen year period. Similarly, when the Stockholm County Council (which runs most of the city’s hospitals) sought tenders for wound care products, it asked suppliers to include calculations for the number of dressing changes, staff and transportation costs for changing these dressings. The winning bid was from the highest priced products which showed a lower cost of care over time.
The Boston Consulting Group report argues that smarter procurement such as these examples embraces a value-based framework that is aligned with the new EU directive. To include all the hidden costs of the equipment in terms of its durability and suitability to patient’s needs, the group suggests a calculation based on patient outcomes divided by the costs of achieving these outcomes.
Carty hopes this more holistic approach to procurement will be embraced by healthcare providers in Ireland. “This new procurement process focuses more on how to achieve better patient outcomes,” he says. Carty also suggests it would encourage clinicians to work more closely with the medical technology industry rather than leaving procurement decisions to those with their eyes firmly placed on the purchase price alone.
A natural extension of this approach would, according to Carty, be for healthcare providers to seek solutions to ongoing problems through industry competitions. This already happens in some countries such as the UK where the Small Business Innovation Research (SBIR) mechanism is used. There, NHS England’s SBRI Healthcare has worked with companies to come up with new solutions to problems in diverse areas such as diabetic foot ulcers, child and adolescent mental health and brain injury. The key element of effective SBIR programmes is that clinicians and front-line staff are the ones to identify the unmet need.
In his role as CEO of IMSTA, Carty proposed the SBIR model to a cross-departmental committee at Government level in 2015.
“We proposed that one to two per cent of the HSE non-pay procurement budget of €500 million could be ring-fenced to find solutions to identified healthcare problems,” he explains. The proposal was repeated in the IMSTA submission to the Oireachtas Committee on the Future of Healthcare in August 2016. As yet, the model hasn’t been embraced by the Health Services Executive.
Now, in 2017, Carty is keen to move the agenda forwards. To that end, Value-Based Healthcare Strategies is the theme of the IMSTA Annual Conference in the Crown Plaza Hotel, Santry on March 22. Confirmed speakers include Dr Tom Kelley from ICHOM, the International Consortium for Health Outcomes Measurement, Bill Maher, the CEO of the Bons Secours Hospital Group and Frank Sullivan, Adjunct Professor in Medicine and Director of Prostate Cancer Institute, NUIG. Throughout the conference, delegates will hear about the role of healthcare innovation in improving patient and clinical outcomes. Proposals for a new economic evaluation framework for medtech will also be discussed.
Ultimately, Carty is keen to spread the message about the role of medical technology companies in helping people live longer, healthier and more productive lives. “These life changing innovations also bring savings across the health care system by replacing more expensive procedures, reducing hospital stays and allowing people to return to work and home more quickly,” says Carty.
However, he adds a note of caution. “In order to understand the value and benefits of medical technology and ensure continued leadership of this industry, we must have the right public policies to support investment, innovation and patient access.”
Article for IMSTA Newsletter, Spring 2017
The European MedTech Week will take place between 19-23 June for the third time across Europe!
In a joint effort, medical technology companies and national associations aim at creating a ‘buzz’ around the positive role of medical technology in healthcare. The past edition received a high positive attention: MedTech Week was in the spotlight in 19 member states through the active engagement of 14 national associations and 23 member companies with 110+ activities organised. See the exciting results in the MedTech Week Magazine here.
The concept is simple: the focus lies on showcasing local activities where industry players engage with their various audiences at national, regional, commune or hospital level. The format and target audience is fully up to the local needs and activities can range from company or hospital visits to radio campaigns, newspaper articles, policy debates, or communication in the social media sphere. The whole idea is not to add workload or to create new projects, but rather to showcase activities that are anyway happening and give them visibility.
We are looking forward to your participation. Please share the date and engage!
IMSTA’s Annual Conference 2017 highlighted the ‘VALUE of medtech’ in achieving quality patient outcomes. Defining ‘value’ in health care is currently trending world-wide, not only from an industry perspective – pharma, medtech and ICT, healthcare providers, clinical communities and academia are all endeavouring to articulate what ‘value’ means to them and how to apply or implement “value-based health care”.
The following presentations are now available for viewing:
“Optimising the Value of medical equipment through implementing holistic equipment management” Mr. Fran Hegarty, Children’s Hospital Group
The Faculty of Nursing & Midwifery, Royal College of Surgeons in Ireland and IMSTA are delighted to announce a new innovative Credentialing Education Programme for Healthcare Industry Representatives (HCIRs) entering healthcare facilities for the purpose of conducting business. The programme aims to enhance the standards of training for HCIRs visiting healthcare organisations, provide assurance to health service and hospital staff and support public and private health service providers fulfil their duty of care to protect patients and ensure safe outcomes. Patient health, safety and confidentiality are the primary focus of the programme.
This bespoke blended-learning programme entitled: “HealthCare Industry Representative Credentialing Programme” will be delivered over 12 hours. The first four hours of the programme will be delivered, in one face-to-face in the RCSI at 9am, and finishing at 13.30pm.
A further 8 hours of content will be delivered on-line via the Faculty’s online “Moodle” Platform. These can be undertaken at a time and location convenient to the participant. Participants will be required to complete a short Multiple Choice Quiz (MCQ) on completion of the programme.
FEEDBACK FROM MEMBER WHO ATTENDED MARCH CREDENTIALING PROGRAMME:
“From an Industry Representative perspective, I feel it is very important to attend the course and attain the Credentialing Card, as our industry and the people we engage with on a daily basis require us to be ethical, compliant and, above all, be competent to ensure better patient care and patient outcomes.”
John Donovan, Sisk Healthcare /MED Surgical
Friday May 5th 2017, 9.00 a.m. in the RCSI, 123 St Stephen’s Green, Dublin 2. Register now below.
Friday 1st September 2017 9.00 a.m. Registration from Monday 8th May 2017.
Registration for May programme is available at http://www.rcsi.ie/fnm_cpdhcir.
Information on the programme is available on the CPD Programmes page of the Faculty’s website http://www.rcsi.ie/fnm_cpd
Requirements Prior to Acceptance on the Programme:
- Completed Application Form- This form contains a section, which must be completed by the Employer, signed, and dated;
Cost : €100.00 per participant
Further Information on this Programme
Ms. Catherine Clune Mulvaney
Operations & Education Manager
Faculty of Nursing & Midwifery
123 St. Stephen’s Green,
T: 01 402 5172 M: 087 6374002
IMSTA are delighted to announce details of our Annual Conference on 22nd March 2017. Titled VALUE-BASED HEALTHCARE STRATEGIES Driving Better outcomes, the Conference this year will again attract a large audience and get significant media attention.
This is a must see event, it will cover the VALUE of the medtech industry to the healthcare system, the economy, healthcare innovation, the new hospital groups and patient and clinical outcomes. Procurement reform and planning capital equipment replacement will also be out front and centre
Medical technology companies create life changing innovations which allow people to live longer, healthier and more productive lives. These advancements also yield savings across the health care system by replacing more expensive procedures, reducing hospital stays and allowing people to return to work and Home more quickly.
“In the US between 1980 and 2010, advanced medical technology helped reduce the duration of hospital stays by 58%” Advamed 2016.
The advanced medical technology industry is fuelled by small businesses and entrepreneurs, providing high quality jobs and economic growth in communities both large and small. In order to understand the value and benefits of medical technology and ensure continued leadership of this industry, we must have the right public policies to support investment, innovation and patient access.
IMSTA’s Annual Conference 2017 will be highlighting the ‘VALUE of medtech’ in achieving quality patient outcomes. Defining ‘value’ in health care is currently trending world-wide, not only from an industry perspective – pharma, medtech and ICT – healthcare providers, clinical communities and academia are all endeavouring to articulate what ‘value’ means to them and how to apply or implement “value-based health care”.
“Achieving high value for patients must become the overarching goal of health care delivery, with value defined as the health outcomes achieved per dollar spent”, i.e. outcomes divided by the cost of achieving those outcomes. (Porter)
We have an excellent line-up of Speakers, including Bill Maher, CEO of the Bons Secours, Frank Sullivan, Adjunct Professor in Medicine and Director of Prostate Cancer Institute, NUIG etc – see Agenda.
The Annual Conference will take place this year in the Crowne Plaza Hotel Northbrook in Santry, Dublin from 8.00 a.m. to 1.30 p.m. Booking is essential and registration will be available shortly on our website www.imsta.ie.
CMC Hygea share their experience of winning the IMSTA Best Primary Care/ Community Service Award at 2016’s IMSTA’s for their product LUCA (Leg Ulcer Cleaning Aid) sponsored by MANGAN O’BEIRNE, Solicitors.
Founded in 2013, CMC Hygea is based in Waterford City and specialises in innovation and design in Antimicrobial Pathogen resistant “Class 1 Medical devices for use in surgical, clinical and community based settings. In recognition of the feedback from Clinicians working in the community for our LUCA (Leg Ulcer Cleaning Aid), we were nominated for the IMSTA award by South East Business and Innovation Centre for our innovative, safe and cost effective product.
We graciously and humbly accepted the nomination on behalf of the hardworking and dedicated team at CMC Hygea Ltd, for their outstanding commitment and loyalty. We were also delighted for the many organisations and state agencies who had faith in what we were trying to accomplish and for their historic and continuing guidance and support. Waterford LEO, Enterprise Ireland, Southeast BIC and the Waterford Institute of Technology, ARC Labs to name but a few, can all take a bow for helping us to overcome the many challenges that we faced as an innovative start up medical devices company.
Enthused with excitement at being nominated for the IMSTA and the prospect of being in the presence of many of our industries “Blue Ribband” companies, we immersed ourselves in the ether of their various positive contribution to the healthcare sector. To top it all, Croke Park was a most fitting backdrop and venue to host such an illustrious industry event and made us feel we had arrived.
The Best Primary Care/Community Service Award category, in which we were nominated, was poignant and dear to our hearts as it ensconced the principles and values of CMC Hygea and best represented our passion and commitment in making a real tangible difference in people’s lives, by aiding recovery and reducing susceptibility to cross infection. In an age of “Superbug bacteria”, it’s wonderful to know that we are contributing to the solution in a positive and progressive way”.
“We were truly in the presence of greatness……
The prestige and importance of the Black-tie event was borne out by the full capacity house and the calibre and scope of the companies in attendance. With representations from large multinationals to indigenous Irish SMEs, we were truly in the presence of greatness.
The IMSTA awards ceremony created a great sense of occasion. The pre-dinner reception in the corporate suite and subsequent tour of the impressive Croke Park location were awe inspiring and inspirational.
Our table was hosted by Mangan O’Beirne Solicitors who were gracious and generous hosts. Being nominated in any category was a tremendous honour for us and our business, but when Michael Lyster announced our name as winner we were in disbelief and somewhat overwhelmed. Our delight, pride and genuine surprise at being bestowed with such an accolade was apparent and plain for all to see.
Our homeward journey was constantly interrupted by a myriad of congratulatory texts and phone calls from well-wishers. We were on “cloud nine”.
Arriving into the office the following morning, with the award in hand, was a powerful feeling which was felt by everyone in our team. The phone calls and texts continued well into the day and the magnitude of our achievement was slowly sinking in. We were honoured and grateful that an award of the calibre of the IMSTA’s was bestowed on us.
Since winning the IMSTA award, we have gone on to even greater success. We have recently secured substantial investment from both Enterprise Ireland and private investors which will allow us to progress on our journey. We have embarked on a roll-out of our products and concepts to the US market place. The journey has posed a number of challenges that, through the support of the industry we have overcome. It has without doubt it has been a worthwhile journey of enlightenment and discovery. Ireland is an incredible country with the infrastructure and supports that can and will facilitate enterprise and innovation. With grit and determination anything is possible and we are living proof that if you believe in yourself and what you are doing, you will succeed.
So now it’s onwards and upwards from everyone involved at CMC Hygea. We are eagerly anticipating the next chapter in the evolution of CMC Hygea and the Pathaguard brand and what dizzying heights we can aspire to”.
Dear Medical Device Stakeholder,
Your industry representative body has kindly agreed to distribute the attached letter (attachment I) on behalf of HPRA.
The purpose of the letter is to inform stakeholders of the new fees that will be implemented from 1 January 2017 and to request contact information so that HPRA can contact organisations directly on the matter of fees.
We could be grateful if you could respond to devicefee@HPRA.ie with the necessary contact details or go to the following website:
Human Products Authorisation & Registration Dept
Health Products Regulatory Authority | An tÚdarás Rialála Táirgí Sláinte
Kevin O’Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2.
Tel: +353 1 676 4971
Fax: +353 1 676 7836